Canada Clinical Trials Group Contribution to NCI Program

该应用程序的最终目标是提高我们可靠有效地回答癌症治疗中关键问题的能力。由于随机临床试验提供了癌症治疗有效性的最佳证据，国家癌症研究所通过癌症治疗评估计划的临床研究分支资助了一个临床试验合作小组计划。在过去的几年里，为了促进研究的更快发展和完成，对临床试验计划进行了实质性的修改 解决癌症治疗中的重要问题。这些变化对包括加拿大在内的整个北美地区的合作临床试验的开展产生了重大影响。 加拿大国家癌症研究所是一个由加拿大癌症协会捐款资助的机构，它支持一个国家临床试验小组（NCIC CTG），其功能与美国小组类似。自1988年以来，NCIC CTG一直由NIH资助，以支持该小组对涉及两个或多个小组之间合作努力的试验的贡献-“组间”试验。本申请的目的是更新和扩大该资金，使NCIC CTG能够积极参与临床试验的“新国家系统”。该提案的具体目标与我们最初申请时的目标相同，即：1.贡献病人 入组、数据管理资源和NCI赞助的组间试验的高质量数据; 2.为NCI组间试验的开发、设计和实施提供科学投入;以及3.为一些NCI组间试验提供领导和协调资源。然而，由于该奖项在过去五年中支持的工作以及临床试验系统的变化，该申请的重点是我们作为北美大型研究领导者的角色。

The ultimate goal of this application is to enhance our ability to answer, reliably and efficiently, critical questions in the treatment of cancer. Because randomized clinical trials provide the best evidence of the effectiveness of cancer treatments, the National Cancer Institute funds a Clinical Trials Cooperative Group Program through the Clinical Investigations Branch of the Cancer Therapy Evaluation Program. In the past few years, substantial changes have been made to the Clinical Trials Program in order to promote the more rapid development and completion of studies that address important issues in cancer treatment. These changes have had a major impact on the conduct of cooperative clinical trials throughout North America, including Canada. The National Cancer Institute of Canada, an agency funded by donations to the Canadian Cancer Society, supports a national clinical trials group (NCIC CTG) that functions similarly to US groups. Since 1988, the NCIC CTG has been funded by NIH to support the Group's contribution to trials that involve a collaborative effort between two or more groups - "intergroup" trials. The purpose of this application is to renew and expand that funding in a manner that will allow the NCIC CTG to participate actively in the "New National System" of clinical trials. The specific aims of the proposal are the same as they were in our initial application; namely: 1. To contribute patient enrollment, data management resources, and high quality data to intergroup trials sponsored by NCI; 2. To provide scientific input into the development, design and conduct of NCI intergroup trials; and 3. To provide leadership and coordination resources for some NCI intergroup trials. However, because of the work supported by this award in the past five years and the changes in the clinical trials system, the emphasis of this application is on our role a leader of large North American studies.